



Study Published in Peer-Reviewed Journal Shows MiSight® 1 day Provides Desirable Myopic Defocus for Higher Prescriptions

Ophthalmic and Physiological Optics Paper Presents Findings on Highly Myopic Eyes

ROCHESTER, N.Y., March 4, 2025—A newly published study in a peer-reviewed journal reinforces prescribing confidence in [CooperVision's](#) MiSight® 1 day soft contact lenses for higher prescriptions, demonstrating their ability to deliver consistent retinal defocus in more prolate-shaped eyes commonly associated with higher myopia. The performance is consistent with the optical profile that has been shown to slow myopia progression in powers to correct low and moderate levels of myopia.*[†]

Recently published in *Ophthalmic and Physiological Optics*, the research journal of the UK's College of Optometrists, [Accommodative Behavior and Retinal Defocus in Highly Myopic Eyes Fitted with a Dual Focus Myopia Control Contact Lens](#) (Meyer D et al.) is now accessible via Open Access.

“This study provides compelling evidence that MiSight® 1 day delivers consistent defocus from the treatment zones across a wide range of myopia levels,” said Paul Chamberlain, Senior Director of Research Programs at CooperVision and one of the paper’s authors. “The research marks the latest data in a years-long collaboration to overcome instrumentation limitations and develop a precise, advanced technique for measuring treatment impact.”

Investigators evaluated teenagers and young adults who had high myopia (–6.50 to –9.25 D).[†] They found that accommodative behavior remained stable fitted with single vision and dual focus lenses. This is particularly relevant as higher levels of myopia are often associated with larger accommodative lags.

Additionally, the work illustrated that MiSight® 1 day achieved significant optical defocus across varying viewing distances and retinal regions. Measured retinal defocus within the annular treatment zone was approximately –2.00 D at the foveal center, 10° nasal and temporal and 20° nasal and reduced to –1.90 (0.57) D at 20° temporal. This consistent level of myopic defocus helps ensure effective optical signaling, which is key to slowing myopia progression in wearers.

These findings strengthen the evidence for MiSight® 1 day in myopia management for higher prescriptions, offering eye care professionals valuable data to guide clinical decisions and contributing to the expanding research on optical interventions for myopia control. For more information on CooperVision's myopia control and management advancements, visit www.coopervision.ca.

* Compared to a single vision 1 day lens over a 3 year period.

† USA Indications for use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal. **Canadian Indications for Use:** MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

References

1 Chamberlain P et al A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci 2019;96:556?567

###

About CooperVision

CooperVision, a division of CooperCompanies (Nasdaq:COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric, and multifocal products available. Through a combination of innovative products and focused practitioner support,

the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 16,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com.

Media Contact

Laura DiCaprio, Senior Counselor

McDougall Communications for CooperVision

Laura@mcdougallpr.com or +1-585-434-2153